Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Prepares To Compete With Genzyme In Gaucher Market With 15% Price Discount

This article was originally published in The Pink Sheet Daily

Executive Summary

During its 2009 earnings call, the company also reported significant sales increase for its Replagal drug for Fabry disease.

You may also be interested in...



Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv

The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share

Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv

The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share

Business News In Brief

Shire's velaglucerase approved: FDA's clearance of Shire's VPRIV (velaglucerase) on Feb. 26 adds a second approved therapy for Gaucher disease, a rare lysosomal storage disorder, to the U.S. market. The action comes at a key time as Genzyme's Cerezyme, the first drug approved for Gaucher, has been in short supply since Genzyme's primary manufacturing facility was shut down for six weeks last summer due to viral contamination. Velaglucerase and Protalix's telaglucerase (Uplyso, now partnered with Pfizer) have been available under emergency use authorization and accepted for accelerated review. VPRIV's safety and efficacy were evaluated based on three clinical trials involving 82 Gaucher patients, including some who switched over from Cerezyme. In announcing the approval, FDA noted that patients who previously received Cerezyme could switch safely to Shire's product. Shire also is seeking approval for velaglucerase in Europe, where its marketing authorization application has been accepted under accelerated assessment (1"The Pink Sheet" DAILY, Feb. 19, 2010)

Related Content

Topics

UsernamePublicRestriction

Register

PS070248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel